This Obesity Startup Thinks GLP-1s Are Yesterday's News

The second program, MW-601, tackles something called PTP1B, a protein that acts like a dimmer switch on your brain's ability to sense fullness. When PTP1B is overactive, your hypothalamus (the brain's appetite control center) becomes resistant to leptin and insulin, two hormones that normally tell you "hey, you've eaten enough." MW-601 is designed to cross the blood-brain barrier and flip that dimmer switch back up. Instead of forcing appetite suppression the way GLP-1s do, it aims to restore your body's natural satiety signals.

The third target, the NLRP3 inflammasome, addresses the chronic, low-grade inflammation that drives insulin resistance and damages organs in obese patients. Mwyngil has multiple NLRP3 inhibitors in development, including BT-409, which can penetrate the brain, and a separate program focused on chronic kidney disease. Clinical trials for the NLRP3 assets are planned for 2026.

Why Investors Are Buying This Story

The company's investors include OrbiMed and Torrey Pines Investment. The company actually grew out of a drug discovery accelerator run by Torrey Pines and OrbiMed, in collaboration with DZNE, a German research institution. It's headquartered across Dover, Delaware and Boston.

The investor interest reflects a broader shift. Analysts now describe the GLP-1 layer as "overcrowded," and the smart money is hunting for what comes next. In Europe, metabolic disorders (including obesity) accounted for approximately 37% of biotech venture investment by mid-2025. Companies like OrsoBio raised $67 million for mitochondrial approaches. Aardvark Therapeutics pulled in $85 million for a non-incretin gut-brain platform before going public. The pattern is clear: VCs want mechanisms that can stand alone or be combined with GLP-1s to create something better than either approach alone.

Mwyngil's explicit framing of GPR75 and NLRP3 as synergistic is worth noting. The company argues that blocking GPR75 handles weight and insulin sensitivity, while NLRP3 inhibition tackles the inflammatory damage to blood vessels, kidneys, and the liver. Together, they could address cardiovascular and renal risk on top of weight loss; something payers increasingly demand before writing big checks.

The Crowded Room Mwyngil Is Trying to Avoid

The GLP-1 market is turning into a gladiator arena. Semaglutide started losing patent exclusivity in major markets in early 2026. Oral GLP-1s launched in late 2025 and are projected to capture 25% of the market by 2030. Pricing is eroding at roughly 7% per year. Payers are increasingly picking one GLP-1 per formulary and telling everyone else to compete on price.

For a late entrant with a "me-too" GLP-1, that math is brutal. You're competing against entrenched brands with years of real-world data, massive supply chains, and incoming generics. It's like opening a new coffee shop across the street from Starbucks and charging more.

Mwyngil's bet is that it doesn't have to play that game at all. By targeting entirely different biology with oral small molecules, the company positions itself as a complement to GLP-1s rather than a competitor. Imagine a world where you take a GLP-1 to lose weight and an MW-401 to keep the muscle, with an NLRP3 inhibitor protecting your kidneys on the side. That's a much more interesting pitch to a payer than "our peptide is 2% better at weight loss."

The Big Question Nobody Can Answer Yet

Of course, contrarian bets are only brilliant in hindsight. GPR75 is still unproven in humans. PTP1B has been a notoriously difficult drug target for decades, with multiple companies failing to crack it. And NLRP3 inhibitors have a mixed clinical track record across various diseases.

Mwyngil's leadership team brings credibility: Greenwood previously co-founded Gallop Oncology and ran the Dana-Farber Cancer Institute's venture fund. COO Nikolay Savchuk doubles as managing partner at Torrey Pines. The scientific advisory bench includes diabetes and metabolism researchers from the University of Chicago and DZNE.

But credibility doesn't equal clinical success. The company needs human data, and that's still at least a year away for its most advanced program. In biotech, a lot can go wrong between "promising mouse data" and "works in people."

Still, in a market where dozens of companies are all chasing the same receptor, there's something refreshing about a startup that says, "We'd rather build something different than fight over the same parking spot." Whether the biology holds up is another story entirely. But the thesis? In an ocean of GLP-1 copycats, it might be exactly what the market needs to hear.

New Drug Prices Just Dropped for the First Time in Years. Don't Celebrate Yet.

Median launch prices for new drugs dropped more than 40% in 2025, falling to $216,000 from over $370,000 the year before. But before you celebrate, the reason has nothing to do with pharma companies charging less.